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Abstract
Intriduction: The aim of presented study was to assess the efficacy of cinacalcet in reducing serum calcium concentrations in primary 
hyperparathyroid (PHPT) patients with hypercalcaemia exceeding 12.5 mg/dL, awaiting parathyroidectomy. 
Material and methods: The study included 23 patients with PHPT with hypercalcaemia > 12.5 mg/dL, qualified for surgery. We recorded 
clinical and biochemical data at baseline, and after every week of treatment. We also monitored adverse events. Cinacalcet was adminis-
tered in increasing doses until the corrected serum calcium concentration was 11.3 mg/dL or less, the patient reached the highest possible 
dosage of 90 mg four times daily, or the patient experienced an adverse event that precluded further dosage increases. 
Results: The primary end point of reduction in corrected serum calcium concentration to 11.3 mg/dL was achieved in 19 patients (83%), 
and normocalcaemia (S-Ca < 10.3 mg/dL) was achieved in 55% of patients. The medication was usually well tolerated (83.4%). Most 
common adverse events were nausea and vomiting, especially at the beginning of therapy; however, only one patient withdrew from 
the study because of adverse events.
Conclusion: Cinacalcet rapidly reduced serum calcium in PHPT patients with severe hypercalcaemia and can be useful as a short-term 
pretreatment prior to surgery, allowing the completion of diagnostics and safe awaiting for operation. (Endokrynol Pol 2017; 68 (3): 306–310)
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Streszczenie
Wstęp: Celem prezentowanej pracy była ocena skuteczności cynakalcetu w kontroli stężenia wapnia w surowicy u chorych na pierwotną 
nadczynność przytarczyc (PHPT) z hiperkalcemią przekraczającą 12,5 mg/dl — w oczekiwaniu na leczenie operacyjne.
Materiał i metody: Badaniem objęto 23 pacjentów z PHPT z hiperkalcemią > 12,5 mg/dl, zakwalifikowanych do leczenia operacyjnego. 
Dane kliniczne i wyniki badań biochemicznych oceniano na początku i po każdym tygodniu leczenia. Monitorowano występowanie 
działań niepożądanych. Cynakalcet podawano w dawkach rosnących, zaczynając od 30 mg dwa razy dziennie, do uzyskania redukcji 
stężenia wapnia w surowicy skorygowanego poniżej 11,3 mg/dl, maksymalnej dopuszczalnej dawki 90 mg cztery razy na dobę, lub 
u pacjenta wystąpiły działania niepożądane, które uniemożliwiły dalsze zwiększanie dawkowania leku.
Wyniki: Obniżenie skorygowanego stężenia wapnia w surowicy poniżej 11,3 mg/dl (pierwotny punkt końcowy) osiągnięto u 19 pacjentów 
(83%), a normalizację stężenia wapnia w surowicy (S-Ca < 10,3 mg/dl) uzyskano u 55% pacjentów. Lek był zwykle dobrze tolerowany 
(83,4%). Najczęstszymi działaniami niepożądanymi były nudności i wymioty, zwłaszcza na początku terapii, jednak tylko jeden pacjent 
wycofał się z badania z powodu działań niepożądanych.
Wnioski: Leczenie cynakalcetem umożliwia szybką redukcję stężenie wapnia w surowicy u pacjentów z ciężką hiperkalcemią w przebiegu 
pierwotnej nadczynności przytarczyc. Może szczególnie być użyteczne jako objawowe przygotowanie przed planowanym leczeniem 
operacyjnym, umożliwiając bezpieczne ukończenie diagnostyki i oczekiwanie na zabieg. (Endokrynol Pol 2017; 68 (3): 306–310)
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Introduction
Primary hyperparathyroidism (PHPT) is the most com-
mon cause of hypercalcaemia in the outpatient setting 
and is usually discovered by routine laboratory testing. 
PHPT is frequently asymptomatic, but its clinical presen-
tation ranges in severity from nonspecific complaints to 
life-threatening hypercalcaemia [1, 2]. Increased serum 
calcium and PTH concentrations mediate the complica-
tions associated with PHPT, including skeletal and renal 
disease, gastrointestinal problems, and neuropsychiatric 
manifestations [3]. The goal of therapy in patients with 
PHPT is to normalise serum calcium and PTH levels, and 
to improve the associated clinical manifestations. Parathy-
roidectomy, the only curative treatment, has a high suc-
cess rate when performed by experienced surgeons [2, 4].
Although in the majority of patients serum calcium 
levels do not exceed the upper limit of normal by more 
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than 1 mg/dL, individual patients present more severe 
hypercalcaemia. These patients often have nonspecific 
symptoms such as fatigue, weakness, anorexia, mild 
depression, and mild cognitive or neuromuscular 
dysfunction, and are at substantial risk of hypercal-
caemic crisis, thus requiring symptomatic treatment in 
anticipation of surgery [3]. Until recently, the standard 
treatment for hypercalcaemia was bisphosphonates [5]. 
Approval of cinacalcet for the symptomatic treatment 
of hypercalcaemia in primary hyperparathyroidism 
creates a new opportunity for emergency stabilisation 
of serum calcium and improvement of the overall well-
being of patients waiting for surgery [5, 6].
The aim of presented study was to assess the efficacy 
of cinacalcet to reduce serum calcium concentrations in 
primary hyperparathyroid patients with hypercalcae-
mia exceeding 12.3 md/dL, awaiting parathyroidectomy. 
Study design
This was an open-label, single-arm, dose-titration study. 
Ethical considerations precluded a control group of 
hypercalcaemic patients with PHPT not receiving cina-
calcet. Study visits occurred weekly. Patients initially 
received 30 mg cinacalcet twice daily. The dosage was 
increased to the next sequential dosage every week, de-
pending on the patient’s serum calcium concentration 
during the previous week and an adverse event assess-
ment. Dosage escalation continued until the corrected 
serum calcium concentration was below 11.3 mg/dL, the 
patient reached the highest possible dosage of 90 mg 
four times daily, or the patient experienced an adverse 
event that precluded further dosage increases. The 
secondary endpoint of the study was the achievement 
of a normal corrected total serum calcium concentration 
of ≤10.3 mg/dL.
Material and methods
Twenty-three patients (16 females, 7 males, aged 28– 
–74 years; mean + SD: 56.9 ± 11.9 years) with PHPT 
and hypercalcaemia > 12.5 mg/dL were enrolled, of 
whom 21 (82%) completed the study. One patient 
discontinued prematurely because of an adverse event 
(because of nausea and vomiting), and one patient was 
lost to follow-up. Baseline characteristics of patients 
are shown in Table I. Six patients had nephrolithiasis, 
18 had low bone mineral density, three had previous 
vertebral fractures, and one had a hip fracture. Arte-
rial hypertension was present in 16% of patients, and 
one had history of peptic ulcer disease. The median 
duration of cinacalcet treatment was 64 days (range 
21–98 days). The median effective cinacalcet dose was 
60 mg twice daily (range 30 mg twice daily to 90 mg 
twice daily) (n = 21). 
Samples of venous blood were taken in the morn-
ing after fasting overnight. Baseline and study blood 
samples were obtained for measurement of serum cal-
cium, phosphorus, albumin, creatinine, and intact PTH 
weekly, after an overnight fast and before the morning 
dose of cinacalcet. Corrected total serum calcium was 
calculated according to the following formulas if albu-
min < 4 g/dL:
Corrected calcium (mg/dL) = measured total cal-
cium (mg/dL) + 0.8 (4.0 – serum albumin (g/dL) 
Serum PTH was measured using an electrochemi-
luminescence (ECLIA) immunoassay (intra-assay 
coefficient of variation 4.2–6.4%; Cobas 8000, Roche 
Diagnostics, USA), the normal range being 15.00–65.00 
pg/mL. Serum calcium, serum phosphorus, serum al-
bumin, and serum creatinine were determined using 
standard methods.
Adverse events were recorded throughout the study. 
Statistical analysis
Results are expressed as mean ± standard deviation. 
The Shapiro-Wilk test was used to assess the normal-
ity of variables distribution and the Student t -test for 
dependent variables to assess the statistical significance. 
The number and percentage of subjects achieving 
a reduction in corrected serum calcium to below 
11.3 mg/dL, and to below the upper limit of the 
normal range (< 10.3 mg/dL), were determined. All 
adverse events were tabulated by body system af-
fected, preferred term within body system (according to 
a modified World Health Organisation Adverse Reac-
tion Terminology directory), seriousness, and relation-
ship to study drug. Data for categorical variables are 
presented as numbers or percentages. 
Results
Changes in serum calcium
The baseline mean ± SD corrected calcium concentra-
tion was 13.33 ± 0.45 mg/d (range 12.7–14.2 mg/dL). 
The primary end point of reduction in corrected serum 
Table I. Basal characteristic of patients (mean ± SD)
Tabela I. Podstawowa charaterystyka pacjentów (średnia 
± SD)
Corrected serum calcium  
(n = 8.4–10.3 mg/dL)
13.33 ± 0.45 mg/dL
Serum phosphorus  
(n = 2.8–5.0 mg/dL)
2.7 ± 0.4 mg/dL
Serum PTH  
(n = 15.00–65.00 pg/mL)
187.84 ± 87.1 pg/mL
Serum creatinine  
(n = 0.50–0.90 mg/dL)
0,89 ± 0,08 mg/dL
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calcium concentration to 11.3 mg/dL was achieved in 19 
patients (83%), and 17 patients (74%) achieved normal 
corrected serum Ca < 10.3 mg/dL. The mean serum 
calcium concentration was reduced significantly to 10.2 
± 0.3 mg/dL, p < 0.001 (Fig. 1) 
Changes in plasma intact PTH
At baseline, the mean ± SD pre-dose serum PTH 
concentration was 187.84 ± 87.1 pg/mL (range 87.55– 
–416.75 pg/mL). At the end of the study, the minimal 
obtained plasma PTH concentrations were highly vari-
able, with a mean ± SD serum PTH concentration of 
134.68 ± 49.78 pg/mL; ranging from 66.1 to 254 pg/mL 
(n = 21) (Fig. 2). The change in the PTH from baseline 
to the end of study was statistically significant (p < 
0.01); however, no patient reached normal serum PTH 
concentration
Changes in other biochemical values
Mean ± SD serum phosphorus levels were in the 
low-normal range at baseline at 2.7 ± 0.4 mg/dL, and 
increased not statistically significantly to 2.9 ± 0.3 mg/ 
/dL, p > 0.01, at the end of the study.
Adverse events
All patients experienced at least one adverse event. 
Nausea, vomiting, and paraesthesias were the most 
common adverse events, occurring in ten (31.25%), six 
(18.75%), and five (15,6%) patients, respectively, and 
considered to be treatment related. Treatment-related 
hypocalcaemia was not seen during the study; however, 
paraesthesias occurred in some patients when serum 
calcium concentrations were within the normal range, 
but significantly lower than at baseline. No patient died 
during the study. One patient withdrew from the study 
because of adverse events.
Discussion
This study demonstrates the ability of cinacalcet to 
substantially lower serum calcium concentrations in 
hypercalcaemic PHPT patients qualified for surgery.
Medical options for treating the skeletal complica-
tions of PHPT include antiresorptive treatments, such 
as bisphosphonates, hormonal replacement therapy 
(HRT), and raloxifene [5]. Bisphosphonates and HRT 
effectively decrease bone turnover and increase BMD 
in PHPT patients; however, none of these antiresorptive 
therapies significantly alters serum calcium or PTH dur-
ing long-term therapy [7–9]. Parenteral administration 
of a more potent bisphosphonate, pamidronate, often 
lowers the serum calcium concentration substantially 
within 48 to 72 hours, with the effect prolonged to ap-
proximately 14 days. Zolendronate, the most potent 
bisphosphonate that is FDA approved for the treat-
ment of hypercalcaemia of malignancy, could also be 
considered in this situation [10].
The calcimimetic cinacalcet is an allosteric modula-
tor of the calcium-sensing receptor (CaSR), which is 
strongly expressed on the surface of parathyroid cells 
as well as in other tissues. Cinacalcet enhances the 
sensitivity of the CaSR to the prevailing extracellular 
calcium, resulting in an increase in the intracellular 
calcium concentration and a concomitant reduction 
in PTH released by the parathyroid gland [11]. The 
calcimimetic cinacalcet, initially intended for the treat-
ment of secondary and tertiary hyperparathyroidism in 
patients with renal failure [12], effectively lowers serum 
calcium and PTH levels during long-term therapy in 
PHPT [13–16]. At present, use of this agent in PHPT 
is limited to control of serum calcium in patients with 
symptomatic hypercalcaemia, who are unable to un-
dergo corrective surgery [5, 17]. 
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Figure 1. Mean corrected serum calcium levels during the study period
Rycina 1. Średnie stężenie skorygowane wapnia w trakcie 
stosowanego leczenia
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Figure 2. Mean serum PTH levels during the study period 
Rycina 2. Średnie stężenie PTH w trakcie stosowanego 
leczenia
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In this study, the all participants were qualified 
for surgery according to the Guidelines for Asympto-
matic PHPT Management (serum calcium > 1.0 mg/dL 
[0.25 mmol/L] above the upper limit of normal) [2]. 
The treatment with cinacalcet resulted in lower serum 
calcium concentrations in almost all patients with 
significant hypercalcaemia and in normalisation of 
calcaemia in nearly 75%, as a short-term pre-treatment 
prior to surgery. The reduction of serum PTH was also 
significant, but it varied among single patients and no 
patient reached normal serum PTH. 
Several studies have demonstrated that cinacalcet 
effectively controls hypercalcaemia while only mo-
destly reducing PTH levels in a heterogeneous sample 
of patients with PHPT, including patients with and 
without an indication for parathyroidectomy and 
patients with a history of failed parathyroidectomy 
[17–21]. In pooled analysis of the data from three 
multicentre clinical trials of cinacalcet in patients with 
PHPT, Peacock et al. [20] examined the efficacy and 
the safety profile of cinacalcet therapy in patients with 
PHPT across a wide spectrum of disease severity, from 
mild to severe, as judged by biochemistry and BMD. 
Cinacalcet treatment rapidly normalised serum Ca 
and thereafter maintained normocalcaemia for the 
length of follow-up. However, relationships between 
baseline serum Ca and effective cinacalcet dose could 
not be accurately established. Although mean plasma 
PTH decreased in all three studies, PTH concentrations 
decreased more slowly than serum Ca concentrations 
and never normalised. The difference in serum Ca and 
PTH responses may reflect cinacalcet actions on CaSRs 
in tissues other than parathyroid glands, particularly 
kidneys, in which it directly reduces tubular reabsorp-
tion of Ca, and perhaps also in bone. 
More recently, similar results were also obtained 
from the first multicentre, international, phase 3 ran-
domised, double-blind, placebo-controlled (RCT) trial 
of cinacalcet in subjects with PHPT who met the criteria 
for parathyroid surgery but were unable to undergo 
parathyroidectomy [21].
Our results are consistent with previous studies and 
demonstrate the stabilisation of serum calcium in the 
medium term. This is the first study, however, devoted 
entirely to the patients selected for surgery. Similar 
results presented Inés Luque-Fernández et al., but in 
their study, patients with progressive hypercalcaemia 
awaiting surgery were only a fraction of the total num-
ber of 34 subjects [22].
Cinacalcet was generally well tolerated when 
titrated to as high as 90 mg two times daily, and the 
overall safety profile of cinacalcet observed in this 
study was generally similar to that observed in previ-
ous trials, across a wide range of PHPT. Nausea and 
vomiting were the most common adverse events, but 
only one patient withdrew from the study due to gas-
trointestinal events. 
An important but unavoidable limitation of this 
study is the single-arm design. Ethical considerations, 
however, precluded enrolment of a control group 
because the patients we studied represent a group 
with high risk of hypercalcaemic complications up to 
hypercalcaemic crisis.
In conclusion, the demonstrated efficacy of cinacal-
cet in reducing (and even normalising) serum calcium 
concentrations in PHPT patients with severe hypercal-
caemia indicate that this intervention can be used as 
a short-term pretreatment prior to surgery, allowing 
the completion of diagnostics and safe awaiting for 
operation.
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